Race Oncology Limited
A speciality pharmaceutical company, Race Oncology Limited (ASX: RAC) pursues later stage drug assets, principally in the cancer field. The company has rediscovered a cancer chemotherapy drug ‘Bisantrene’ that has worked effectively in the treatment of several cancers.
The company has received an approval lately from Israeli Ministry of Health and the hospital’s Research Ethics Committee to conduct a trial of Race’s cancer drug, Bisantrene, at the Sheba Medical Center in Israel. Race Oncology CEO, Peter Molloy calls it a significant development as the drug will be used again for the first time since it disappeared more than 25 years ago.
Below is the company’s financial performance as per recently released half yearly report:
The company’s stock ended up lower on ASX at AUD 0.071 (As on 17th May 2019), down by 13.41 per cent. The company’s market cap was noted at AUD 6.74 million.
Zoono Group Limited
Headquartered in New South Wales, Australia, Zoono Group Limited (ASX: ZNO) deals in the, development and global distribution of a unique range of antimicrobial solutions that are long-lasting and environmentally friendly. The company has a world-wide network of distributors and customers that are extended over 42 countries and territories.
On 13th May 2019, the company announced its partnership with New Zealand based ‘The Z Factor Limited’ for the supply of its proprietary poultry formulation. The company has also signed a distribution agreement with Zoono USA LLC and MicroSonic LLC for the supply of its innovative antimicrobial products to Turtle Wax, Inc.
The company’s stock ended the day’s trade at AUD 0.160 on 17th May 2019, down by 3.03 per cent in comparison to the last closing price, with the market cap of AUD 26.95 million. The stock has performed well in the past as it delivers a YTD return of 89.66 per cent. The stock has generated a return of 94.12 per cent, 70.10 per cent and 66.67 per cent in the last six months, three months and one month respectively.
Hipo Resources Limited
Hipo Resources Limited (ASX: HIP) is a company located in Australia that deals in the identification, acquisition, exploration and if warranted, development of mineral assets.
Last week, the company released an update on the lithium-ion battery technology company ‘NextBattery’ in which it holds 25 per cent interest. The company informed that Next Battery will undertake strategic funding round to ensure the final development of commercial prototypes and to improve the existing relationships considerably. As per the recently released quarterly results for the period ending 31st March 2019, Hipo Resources reported a cash balance of $704,000 at the end of the quarter. The company announced key updates regarding its Busumbu Uganda Phosphate Project (24% carried interest African Minerals as the farm-in operator) and Kamola Lithium Project, DRC (60% interest in the JV with Crown Mining Sarl).
The stock price at the end of the day was AUD 0.011 (As on 17th May 2019), a rise of 10 per cent in comparison to the previous close. The 52-week high and low value was recorded as AUD 0.033 and AUD 0.009 respectively.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.